CAU
REGN icon

Caxton Associates (UK)’s Regeneron Pharmaceuticals REGN Stock Holding History

Caxton Associates (UK)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-616
Closed -$323K – 898
2025
Q2 		$323K Sell
616
-222
-26% -$124K 0.01% 523
2025
Q1 		$531K Buy
+838
New +$576K 0.02% 465

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caxton Associates (UK)'s REGN Position: Q3 2025 in Review

Caxton Associates (UK) sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 616 shares — an estimated $323K sold.

Caxton Associates (UK) first reported a position in REGN in Q1 2025 and held it in 2 quarters. The position peaked at $531K in Q1 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Caxton Associates (UK) reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 616 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $323K.
  • Caxton Associates (UK) first reported a position in Regeneron Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s Regeneron Pharmaceuticals position peaked at $531K in Q1 2025.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Caxton Associates (UK)'s 13F filing for Q3 2025, filed 17 Nov 2025.